ArticleJournal of hematology & oncology2022

In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.

Zhichen Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.